ADReCS

Pharmaceutical Information

Drug Name	Saxagliptin
Drug ID	BADD_D01992
Description	Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Indications and Usage	Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Marketing Status	approved
ATC Code	A10BH03
DrugBank ID	DB06335
KEGG ID	D08996
MeSH ID	C502994
PubChem ID	11235729
TTD Drug ID	D0K9MY
NDC Product Code	50193-4212; 0310-6100; 0310-6105; 11722-078; 0310-7100; 50370-0030; 55154-6931; 0310-7105
UNII	9GB927LAJW
Synonyms	saxagliptin \| 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate \| Onglyza \| BMS 477118 \| BMS477118 \| BMS-477118

Chemical Information

Molecular Formula	C18H25N3O2
CAS Registry Number	361442-04-8
SMILES	C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Pruritus	23.03.12.001	0.001997%
Purpura	24.07.06.005; 23.06.01.004; 01.01.04.003	-	-
Rash	23.03.13.001	0.006220%		Not Available
Renal disorder	20.01.02.002	0.000327%		Not Available
Renal failure	20.01.03.005	0.000818%		Not Available
Sinusitis	22.07.03.007; 11.01.13.005	-	-
Skin disorder	23.03.03.007	-	-	Not Available
Skin exfoliation	23.03.07.003	0.000327%		Not Available
Skin ulcer	24.04.03.007; 23.07.03.003	0.000327%
Thrombocytopenia	01.08.01.002	0.000884%		Not Available
Tuberculosis	11.04.01.006	-	-	Not Available
Upper respiratory tract infection	11.01.13.009; 22.07.03.011	-	-
Urinary tract infection	20.08.02.001; 11.01.14.004	-	-
Urticaria	23.04.02.001; 10.01.06.001	-	-
Vision blurred	17.17.01.010; 06.02.06.007	0.002390%
Vomiting	07.01.07.003	0.002815%
Acute coronary syndrome	02.02.02.015; 24.04.04.011	0.000327%		Not Available
Musculoskeletal discomfort	15.03.04.001	-	-	Not Available
Dyslipidaemia	14.08.04.015	-	-	Not Available
Salmonella sepsis	11.02.19.002	-	-	Not Available
Adverse event	08.06.01.010	0.001048%		Not Available
Cardiac disorder	02.11.01.003	0.000327%		Not Available
Infestation	23.11.01.002; 11.09.01.001	-	-	Not Available
Malnutrition	14.03.02.004	-	-	Not Available
Decreased appetite	14.03.01.005; 08.01.09.028	0.000982%
Erectile dysfunction	21.03.01.007; 19.08.04.001	-	-
Immunodeficiency	10.03.02.002	-	-	Not Available
Pancreatic neoplasm	16.13.11.005; 07.21.09.004	0.000327%		Not Available
Renal impairment	20.01.03.010	0.004321%		Not Available
Chronic kidney disease	20.01.03.017	-	-

The 4th Page First Pre 4 5 Next Last Total 5 Pages